Sierra Health and Life HBOT Coverage Update

Coverage Criteria for Hyperbaric and Topical Oxygen Therapy

inv-01: Medically Necessary Indications

HBOT is medically necessary for the following conditions when clinically indicated and provided in accordance with accepted standards of care:

Medically necessary indications list: Acute traumatic peripheral ischemia/insufficiency (e.g., crush injury, reattachment, compartment syndrome); Air or gas embolism; Severe anemia when transfusion refused/delayed/unavailable; Avascular necrosis (aseptic osteonecrosis); Carbon monoxide poisoning; Central retinal artery occlusion; Chronic refractory osteomyelitis; Clostridial myonecrosis (gas gangrene); Compromised skin grafts/flaps; Cyanide poisoning associated with CO poisoning; Decompression sickness; Delayed radiation injuries (soft tissue and bony necrosis); Diabetic lower extremity wounds; Idiopathic sudden sensorineural hearing loss (ISSHL); Intracranial abscess; Necrotizing soft tissue infections; Thermal burns (second or third degree)

List extracted verbatim from policy

inv-02: Not Medically Necessary / Unproven

Noncovered or unproven therapies per policy:

Unproven/Not medically necessary: HBOT for indications not listed as medically necessary; Mild hyperbaric oxygen therapy (mHBOT, devices delivering <1.4 ATA) for any indication; Topical Oxygen Therapy (TOT) for treatment of wounds or ulcers as a routine therapy (except where TOT is specifically described as an adjunct under limited guideline conditions).

Policy states insufficient evidence for efficacy and excludes mHBOT/TOT as medically necessary in general

inv-03: Avascular necrosis (AVN)

Avascular necrosis (femoral head necrosis):

AVN summary: Meta-analysis reported significant clinical improvement with HBOT in early-stage femoral head necrosis (pooled OR = 3.84, 95% CI 2.10–7.02); professional bodies (ECHM, UHMS) suggest or recommend HBOT in early Ficat stages (I–III/early) as part of a multidisciplinary plan rather than as sole therapy.

Limitations noted due to quantity and quality of trials; larger RCTs recommended.

inv-04: Carbon monoxide poisoning

Carbon monoxide (CO) poisoning:

CO poisoning summary: Randomized trials and meta-analyses report mixed results regarding reduction of neurologic sequelae with HBOT versus normobaric oxygen; some analyses show fewer neuropsychological sequelae after HBOT. Society guidance (ECHM, UHMS) broadly recommends HBOT for many CO-poisoned patients (including pregnant or altered patients) with earlier treatment associated with greater benefit; ACEP notes selected symptomatic patients may benefit depending on severity and availability.

Genetic modifiers (APOE epsilon4) may affect response but are not available at presentation; clinical severity and timing guide therapy selection.

inv-05: Central retinal artery occlusion

Central retinal artery occlusion (CRAO):

CRAO summary: Systematic reviews/meta-analyses of RCTs and small studies report improved visual acuity with oxygen therapy, with 100% oxygen and hyperbaric oxygen (>9 hours total) associated with significant visual improvement. Societies (ECHM, UHMS) recommend urgent consideration of HBOT, ideally within 24 hours of symptom onset; UHMS describes initial 90-minute treatment and up to USN TT6 for first treatment.

Optimal number of subsequent treatments depends on clinical response.

inv-06: Refractory osteomyelitis

Chronic refractory osteomyelitis:

Osteomyelitis adjunctive HBOT: Adjunctive HBOT may be considered for chronic refractory osteomyelitis after adequate medical and surgical management; observational series report high remission rates (median ~89%) and societies (ECHM, UHMS) suggest HBOT with combined culture-directed antibiotics and surgical debridement. ECHM suggests prolonged courses (approximately 11–12 weeks, ~60 sessions) may be required before effect is expected.~60 sessions suggested by ECHM

Evidence largely observational; HBOT considered adjunctive to antibiotics and surgery.

inv-07: Compromised skin grafts and flaps

Compromised skin grafts and flap salvage:

Grafts/flaps summary: Evidence quality is low and insufficient to conclusively determine HBOT effectiveness for compromised grafts and flaps. Retrospective series report mixed outcomes (e.g., mastectomy flap ischemia improved in many but not all cases). ECHM and UHMS suggest early HBOT as part of multidisciplinary care and recommend starting HBOT as soon as compromise appears; ECHM protocols propose intensive early dosing (multiple sessions first day).

Authorization should document prior management, underlying cause identification, and rationale; routine authorization without supportive documentation may be denied.

inv-08: Decompression sickness

Decompression sickness (recompression therapy):

Decompression sickness summary: Recompression therapy with HBOT is the standard of care for decompression illness and air/gas embolism despite limited randomized trial evidence; practice guidance (UHMS) endorses HBOT as the mainstay treatment for these life-threatening conditions.

Although RCT evidence is limited, recompression therapy is widely accepted clinically.

inv-09: Decompression illness / air or gas embolism

Covered when ALL of the following are met

Primary indication: Recompression therapy/HBOT is accepted as standard of care for decompression illness and air or gas embolism when clinically indicated (life-threatening conditions with limited alternatives).

Supported by Cochrane review and UHMS/ECHM statements

inv-10: Delayed radiation tissue injury (including osteoradionecrosis, hemorrhagic cystitis, proctitis, soft tissue radionecrosis)

Covered when ALL of the following are met

Radiation injury indication: Persistent or late radiation tissue injury (osteoradionecrosis, hemorrhagic radiation cystitis, proctitis, or soft tissue radionecrosis) following prior radiotherapy where HBOT is intended to improve mucosal or soft tissue healing, reduce wound breakdown, or achieve symptomatic remission.

Supported by systematic reviews and society guidance; documentation should show prior radiotherapy and clinical need.

Treatment course: Typical HBOT regimen for delayed radiation injury is commonly 30–60 treatments at 2.0–2.5 ATA for 90–120 minutes.30-60 sessions

UHMS recommendation

inv-11: Diabetic foot ulcers (DFU)

Covered with criteria — HBOT as adjunctive therapy

Severity and prior care: Patient has a Wagner Grade 3 or higher diabetic foot ulcer (DFU) OR a DFU that has failed to demonstrate significant improvement (>50% wound area reduction) after a minimum of 4 weeks (SVS) or 4–6 weeks (IWGDF) of optimal standard wound care.Wagner >=3; failure of 4-6 weeks standard care

Society guidance (SVS/IWGDF/UHMS) requires documentation of prior optimal care

Adjunctive use: HBOT is provided as an adjunct to standard wound care and, when appropriate, vascular intervention; documentation must show adequate perfusion or prior vascular treatment if indicated.

HBOT should not replace standard care

Expected benefits: Evidence shows HBOT can increase short-term complete healing rates and in some meta-analyses reduce major amputation rates, though long-term benefits are less consistent across studies.

Multiple RCTs and systematic reviews summarized in policy

inv-12: Diabetic Foot Ulcer — Adjunctive HBOT

Covered when ALL of the following are met (Diabetic foot ulcers per guidelines):

DFU HBOT coverage criteria: Adjunctive HBOT may be used for ischemic DFUs that have failed to heal after 4-6 weeks of optimal clinical care (IWGDF) or for Wagner Grade 3 or higher DFUs that have not shown significant improvement after ~30 days of treatment; postoperative HBOT may be added after surgical debridement of infected foot to reduce risk of major amputation (UHMS).timeframes: 4-6 weeks or ~30 days; Wagner Grade >=3

Prior authorization should document wound severity, prior care and dates

inv-13: Sudden Sensorineural Hearing Loss — Adjunctive HBOT

Covered when ALL of the following are met (SSNHL):

SSNHL HBOT coverage criteria: HBOT as adjunct to medical therapy (typically corticosteroids) for acute idiopathic sudden sensorineural hearing loss presenting within 14 days of symptom onset; salvage combination therapy may be considered up to one month. Documentation must include onset date and prior/concurrent steroid therapy. Evidence supports greater benefit when used early and in severe/profound hearing loss.<=14 days preferred; <=30 days salvage

AAO-HNS, ECHM, and UHMS guidelines support early combined therapy

inv-14: Intracranial Abscess — Adjunctive HBOT

Covered when ANY of the following are present (Intracranial abscess):

Intracranial abscess HBOT criteria: Adjunctive HBOT may be considered for intracranial abscesses with any of: multiple abscesses; deep or dominant location; compromised host; contraindication to surgery or poor surgical risk; lack of response or clinical deterioration despite standard surgical and antibiotic therapy. Multidisciplinary team involvement (neurosurgery, infectious disease) is recommended.clinical judgement

Evidence derives from small cohorts and observational series; document rationale and multidisciplinary plan

inv-15: Necrotizing Soft Tissue Infection — Adjunctive HBOT

Covered when ALL of the following are met (Necrotizing soft tissue infections):

NSTI HBOT criteria: HBOT may be used as an adjunct to standard surgical debridement and appropriate antibiotics when available and should not delay definitive surgical or critical care management; meta-analyses and pooled observational data indicate reduced mortality and possible reduction in major amputation odds. Document concurrent standard therapy and availability of HBOT.clinical judgement

Optimal dosing and schedule remain uncertain; HBOT availability must not delay care

inv-16: Thermal Burns — Adjunctive HBOT

Covered when ALL of the following are met (Thermal burns):

Burns HBOT criteria: HBOT may be considered as an adjunct for partial-thickness (second-degree) burns >20% total body surface area (BSA) and/or burns involving critical sites (face, neck, hands, feet, perineum) even if <20% BSA; treatment should be delivered by specialized HBOT centers in proximity to burn centers and not delay standard burn care.>20% BSA or critical site involvement

ECHM and UHMS guidance recommend specialized center involvement and adjunctive use

inv-17: HBOT for burns

Covered when ALL of the following are met (per UHMS guidance):

UHMS burn HBOT criteria: Patient has thermal burn that is >=20% total BSA and/or involves hands, face, feet, or perineum; HBOT goals include minimizing edema, preserving marginal tissue, protecting microvasculature, enhancing host defenses, and promoting wound closure. Treatment should be adjunctive to standard burn care at specialized centers.>=20% BSA or critical site involvement

Based on UHMS 2019 and 2023 indications

inv-18: Topical Oxygen Therapy (TOT) — adjunctive DFU

Covered when ALL of the following are met:

TOT adjunct for DFU: Non-infected diabetic foot ulcer (Wagner 1–2) that has failed to heal after 4–6 weeks of optimal standard care (debridement, offloading, moist wound care); TOT used as adjunctive therapy with documented prior standard care and clinical rationale referencing RCTs/meta-analyses showing increased short-term healing rates.failed 4-6 weeks standard care

IWGDF and recent meta-analyses support adjunctive TOT for selected Wagner 1–2 DFUs; limitations and need for further research noted

The policy classifies mild hyperbaric oxygen therapy (mHBOT) and topical oxygen therapy (TOT) as unproven and not medically necessary for wound and ulcer indications. The document states that mHBOT devices operate at pressures <1.4 ATA and do not meet the clinical definition of HBOT, and that conclusions of benefit for mHBOT are based on animal data, small uncontrolled studies, or anecdote. Similarly, TOT lacks sufficient high-quality evidence to support routine wound or ulcer treatment and is described as not medically necessary for these indications.

For compromised skin grafts and flaps the policy acknowledges the available studies are low quality and insufficient to be conclusive. While some retrospective series report possible benefit (for example, improved SKIN scores and partial recovery without re-operation in a proportion of mastectomy flaps), the overall evidence is too limited to support routine, unconditional coverage; requests may be reviewed on a case‑by‑case basis with documentation of timing, severity, and prior management.

The policy notes that HBOT is not suggested for diabetic foot ulcers with Wagner Grade 2 or lower. UHMS guidance specifically recommends HBOT for Wagner Grade 3 or higher DFUs or ulcers that have failed to improve after the specified period of optimal care, and therefore use in lower Wagner grades is not supported.

The policy summarizes society positions (including UHMS and ECHM): UHMS lists accepted HBOT indications and recommends HBOT for specified conditions (e.g., DFU Wagner Grade ≥3, delayed radiation injury) while also advising that some indications lack sufficient evidence. UHMS and ECHM position statements caution against routine use of low‑pressure chambers and indicate topical oxygen currently lacks the evidence base to be recommended as routine therapy.

The rationale for excluding mHBOT and many low‑pressure chambers is that they operate at pressures below the policy's HBOT threshold (<1.4 ATA) and therefore do not meet the UHMS definition of therapeutic HBOT. Evidence for mHBOT effectiveness is limited to animal or small uncontrolled studies, does not reliably increase tissue oxygenation to therapeutic levels, and may delay effective therapies; for TOT, UHMS and other assessments conclude that evidence is insufficient to support routine clinical use.

This Medical Policy is intended as informational guidance only. Coverage determinations are governed by the member's specific benefit plan document and any applicable federal or state mandates; in the event of a conflict the member specific benefit plan governs. The policy does not substitute for individualized clinical judgment or plan‑level coverage rules.

Restating the policy position: mHBOT is unproven and not medically necessary for any indication, and TOT is unproven and not medically necessary for treatment of wounds or ulcers due to insufficient evidence of efficacy. The devices and techniques that do not meet the HBOT pressure/oxygen definitions are therefore not considered therapeutic HBOT under this policy.

Because the quality of evidence for HBOT in compromised grafts and flaps is low, the policy implies routine use without supportive clinical documentation is not supported; authorizations for these indications should include clinical rationale and timing to allow case‑by‑case consideration.

Although recompression therapy (HBOT) is considered the standard of care for decompression illness and air/gas embolism, the policy notes there are no randomized controlled trials demonstrating superiority; the lack of RCT evidence is acknowledged despite clinical acceptance of HBOT for these life‑threatening conditions.

The policy states that use of HBOT outside the specified, guideline‑supported indications lacks reliable data from well‑designed clinical studies and therefore such uses may be considered not medically necessary and can be denied in the absence of convincing supporting evidence.

Reiterating key exclusions: indications not listed as medically necessary and therapies that do not meet the HBOT definition (notably mHBOT) are unsupported by adequate evidence; requests for these therapies should be disfavored pending higher‑quality data.

Referenced Codes and Technical Definitions

Referenced CPT/Service CodesCPT

99183

Physician or other qualified health care professional attendance and supervision of hyperbaric oxygen therapy, per session

Referenced HCPCS Supplies/DevicesHCPCS

A4575	Topical hyperbaric oxygen chamber, disposable
E0446	Topical oxygen delivery system, not otherwise specified, includes all supplies and accessories

Referenced HCPCS/Procedure CodesHCPCS

G0277

Hyperbaric oxygen under pressure, full body chamber, per 30 minute interval

inv-33: HBOT pressure threshold — numeric definition for therapeutic HBOT

Numeric threshold>= 1.4 ATA

Clinical requirementBreathing near 100% oxygen while chamber pressure equals or exceeds 1.4 ATA

Devices below thresholdTherapies delivered at <1.4 ATA (mHBOT) do not meet the HBOT definition

inv-34: HBOT treatment course — typical course length and pressure/time parameters

Typical course length30 to 60 treatments

Pressure range2.0–2.5 ATA per treatment

Prior Authorization, Documentation, and Billing Guidance

Prior Authorization

Prior Authorization and Plan Reference Requirements

Prior authorization is required for billed HBOT, mHBOT, and TOT services. Authorization requests must state the indication, supporting clinical rationale, and cite member-specific benefit plan requirements. Where Medicare guidance applies (NCD/LCD) include that documentation. Requests for mHBOT or low‑pressure chambers (<1.4 ATA) and for TOT should explicitly justify why standard HBOT is not used; note that mHBOT and many low‑pressure devices do not meet the defined therapeutic HBOT pressure and are frequently considered unproven and at high risk for denial.

Include date of onset and prior treatment dates where applicable
Reference applicable Medicare NCDs/LCDs or member plan mandates

Prior Authorization

Authorization Requirements for Refractory Osteomyelitis and Compromised Grafts/Flaps

For osteomyelitis and compromised grafts/flaps, prior authorization must document that the infection or tissue compromise is refractory to appropriate medical and surgical management and provide the multidisciplinary rationale for HBOT as an adjunct. Documentation should include culture-directed antibiotic regimens, operative reports for debridement or graft/flap details, and the identified underlying cause(s) of compromised perfusion.

Background and Evidence Summary

HBOT is delivered by having the patient breathe near 100% oxygen inside a pressurized chamber at or above 1.4 ATA. Chambers are typically Class A (multi‑place) or Class B (mono‑place); mild hyperbaric chambers operate at lower pressures and topical oxygen systems apply oxygen directly to a wound surface rather than providing systemic hyperbaric exposure. Therapeutic effects depend on achieving the defined pressure/oxygen parameters.

Key Definitions

inv-64: HBOT — definition and clinical delivery parameters

DefinitionHyperbaric Oxygen Therapy (HBOT): intermittent breathing of near 100% oxygen inside a chamber pressurized to >=1.4 ATA

Delivery systemsClass A (multiplace) and Class B (monoplace) chamber configurations; patients breathe near 100% O2 via masks, hoods, or ambient chamber oxygen depending on system

Clinical rolesUsed as primary or adjunctive therapy depending on indication and standard of care

inv-65: mHBOT — definition for mild hyperbaric oxygen therapy and regulatory status

DefinitionMild Hyperbaric Oxygen Therapy (mHBOT): low-pressure fabric chambers delivering pressures <1.4 ATA (mild compression) while breathing air or supplemental oxygen

Regulatory status

Policy Revision History

2026-01-01Policy effective / template updateLatest

Created shared policy version (2026T0632I) with template updates to support application to Oxford plan membership and consolidated prior documents; archived prior policy versions 2025T0632H and OUTPATIENT 051.5.

OpenPayer

Hyperbaric Oxygen Therapy and Topical Oxygen Therapy